Imaging test for detecting and grading myelofibrosis in adults
Tests a PET/CT scan using 68Ga-FAPI to detect and grade myelofibrosis in adults.
Plain-language title generated from the registry record
Registry title: 68Ga-FAPI PET/CT Imaging for Diagnosis, Grading, and Efficacy Evaluation of Myelofibrosis.
Key facts
- Where
- Xiamen, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with suspected or confirmed myelofibrosis, to test a 68Ga FAPI PET/CT scan for diagnosis and grading of fibrosis.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Cohort 1: suspected or confirmed myelofibrosis. Cohort 2: primary or secondary myelofibrosis.
- Earlier treatment
- Cohort 2: people who were not treated with ruxolitinib.
Main reasons for not taking part
- Known allergy to 68Ga FAPI or its ingredients
- Cannot tolerate a drug given into a vein, or cannot complete a PET scan (for example fear of closed spaces)
- Pregnant or breastfeeding women
- Serious heart, kidney, lung, blood vessel, nerve, mental or immune diseases, or hepatitis/cirrhosis
- Chemotherapy, immunotherapy or targeted therapy for another cancer
Read by machine on 12 November 2026.
Where in China
- Bing XuXiamen, ChinaContact: Bing XuTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- The First Affiliated Hospital of Xiamen University
- Trial code
- NCT06151119
- Record updated
- 19 February 2025
- Original description
To evaluate the diagnostic efficacy of 68Ga FAPI PET/CT in myelofibrosis and to identify fibrosis grades.Read full original descriptionShow less
A Study to Evaluate 68Ga-FAPI PET/CT Imaging for Diagnosis, Grading, and Efficacy Evaluation of Myelofibrosis.
To evaluate the diagnostic efficacy of 68Ga FAPI PET/CT in myelofibrosis and to identify fibrosis grades.
To evaluate the diagnostic efficacy of 68Ga FAPIPET/CT imaging in patients with myelofibrosis, compared with conventional CT.
Inclusion: Age ≥18 years old; Cohort 1: Patients with suspected or confirmed myelofibrosis; Cohort 2: Patients with primary/secondary myelofibrosis who were not treated with ruxolitinib; The expected survival time is over 3 months; Voluntarily sign informed consent; Willing and able to follow the research protocol; The subject must be able to lie on the scanning bed for 20 minutes.
Exclusion: Patients who can not tolerate intravenous drug administration (such as needle fainting and blood fainting history); Workers who are exposed to radiation for a long period of time; Participating in other interventional clinical trials within 1 month before screening; Known allergic history to 68Ga FAPI or its excipients; Serious diseases of the heart, kidney, lung, blood vessel, nervous system, mental system, immune deficiency diseases and hepatitis/cirrhosis; Patients undergoing chemotherapy, immunotherapy or molecular targeted therapy due to other cancers; Those who are not suitable for or unable to complete imaging tests such as PET due to special reasons, including claustrophobia and radiophobia; pregnant and lactating women; There are other circumstances that the researcher thinks are not suitable for participating in this study.